I had a closer look at Dr Abeyratne's UQ profile and I noticed Appian Medical listed as one of his spin-off companies.
Appian Medical originally attempted to commercialise Abeyratne's Sleep Apnea algorithms but it looks like they ended up closing up shop.
Appian had completed only two clinical trials at the University of Queensland. The first one has 41 patients and the second had 86. Its easy to see why ResApp's OSA project has been bubbling along in the background as Dr Abeyratne figured out this project was going nowhere, developed new algorithms with ResApp and found it cost effective running clinical trials on over 700 patients.
Management of Appian were former ISN Directors and the company almost listed on the ASX a year before ResApp. They were looking to raise $8-$10M. Here is their investor deck with plenty of compelling statistics http://appianmed.com/wp-content/upl...ical-Investor-Presentation-September-2014.pdf
Its almost as if ResApp has acquired another company with this new market and product which alone could be a unicorn.
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp Develops Obstructive Sleep Apnoea Screening Test
RAP
raptor metals ltd
Add to My Watchlist
9.09%
!
3.0¢
Ann: ResApp Develops Obstructive Sleep Apnoea Screening Test, page-106
-
Top Stories
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
